Literature DB >> 33568198

Can eosinophilia and neutrophil-lymphocyte ratio predict hospitalization in asthma exacerbation?

Hossein Esmaeilzadeh1,2, Fatemeh Nouri3, Seyed Hesamodin Nabavizadeh1,2, Soheila Alyasin1,2, Negar Mortazavi4.   

Abstract

OBJECTIVE: Asthma is one of the most common diseases amongst children. Blood eosinophil count and neutrophil-lymphocyte ratio (NLR) are known as markers for phenotyping asthma. This study was performed to investigate blood eosinophil count and NLR as predictors of hospitalization in pediatric asthma exacerbations. DATA SOURCES AND STUDY SELECTIONS: In this cross-sectional study, children admitted to hospital ward for more severe asthma exacerbation were compared with non-hospitalized children with moderate to severe asthma exacerbation whose asthma exacerbation was managed in emergency department or outpatient clinic. We investigated patients' characteristic and factors associated with hospitalization.
RESULTS: A total of 211 children with moderate to severe asthma exacerbation (mean age [Formula: see text] years old) were enrolled in the study including 91 hospitalized patients and 120 non-hospitalized patients. For the prediction of hospitalization, an ROC Curve analysis was performed and revealed a cut-off of 298 cells/µL and 2.52 of blood eosinophil count and NLR, respectively. In multivariate analysis, not using an asthma action plan (OR 2.22, 95% CI 1.09-4.49; P = 0.027), a blood eosinophil count [Formula: see text] 298 (OR 8.79, 95% CI 4.44-17.4; P < 0.001) and an NLR [Formula: see text] 2.52 (OR 2.13, 95% CI 1.09-4.14; P = 0.027) were associated with hospitalization.
CONCLUSION: Blood eosinophil count and NLR were found to be higher in hospitalized children with more severe asthma exacerbation compared to non-hospitalized patients. These markers can be indicators for asthma exacerbation severity.

Entities:  

Keywords:  Asthma; Asthma exacerbation; Blood eosinophil count; Eosinophil; Neutrophil–lymphocyte ratio

Year:  2021        PMID: 33568198      PMCID: PMC7874466          DOI: 10.1186/s13223-021-00512-x

Source DB:  PubMed          Journal:  Allergy Asthma Clin Immunol        ISSN: 1710-1484            Impact factor:   3.406


  34 in total

1.  The state of childhood asthma, United States, 1980-2005.

Authors:  Lara Akinbami
Journal:  Adv Data       Date:  2006-12-12

Review 2.  The reclassification of asthma based on subphenotypes.

Authors:  Ruth H Green; Chris E Brightling; Peter Bradding
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-02

3.  A role for neutrophils in asthma exacerbations.

Authors:  William W Busse
Journal:  Nat Med       Date:  2017-06-06       Impact factor: 53.440

4.  Asthma exacerbations in a tertiary hospital: clinical features, triggers, and risk factors for hospitalization.

Authors:  B Pola-Bibian; J Dominguez-Ortega; G Vilà-Nadal; A Entrala; L González-Cavero; P Barranco; N Cancelliere; M Díaz-Almirón; S Quirce
Journal:  J Investig Allergol Clin Immunol       Date:  2016-12-14       Impact factor: 4.333

5.  [Clinical significance of peripheral blood neutrophil-lymphocyte ratio and platelet- lymphocyte ratio in patients with asthma].

Authors:  Guang Shi; Jun-Wei Zhao; Liang Ming
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

6.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.

Authors: 
Journal:  Eur Respir J       Date:  2003-09       Impact factor: 16.671

7.  Blood Eosinophil Count and Outcomes in Severe Uncontrolled Asthma: A Prospective Study.

Authors:  Robert S Zeiger; Michael Schatz; Anand A Dalal; Wansu Chen; Ekaterina Sadikova; Robert Y Suruki; Aniket A Kawatkar; Lei Qian
Journal:  J Allergy Clin Immunol Pract       Date:  2016-09-21

8.  Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation.

Authors:  Christina Miranda; Ashley Busacker; Silvana Balzar; John Trudeau; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2004-01       Impact factor: 10.793

9.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

10.  The Effectiveness of Written Asthma Action Plan at the National Guard Health Affairs' Asthma Clinic.

Authors:  Loie Goronfolah; Alwalla Abulaban; Ahlam I Barnawi; Maram Jawi; Wejdan Alhadhrami; Nada Y Baatiah
Journal:  Cureus       Date:  2019-11-27
View more
  1 in total

1.  The Neutrophil/Lymphocyte Ratio is an Independent Predictor of All-Cause Mortality in Patients with Idiopathic Hypereosinophilic Syndrome.

Authors:  Junshuai Xue; Jianjun Jiang; Yang Liu
Journal:  J Inflamm Res       Date:  2022-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.